Novel Tool Developed to Detect and Identify Pathogens
|
By LabMedica International staff writers Posted on 28 Sep 2021 |

Image: The workflow of the HUBDesign pipeline: Probe design for simultaneous, targeted capture of diverse metagenomic targets (Photo courtesy of McMaster University)
Pathogens in clinical or wildlife settings samples of blood or saliva, for example, are particularly challenging to isolate, since they can easily make up less than one one-millionth of a sample, especially in early stages of an infection, when concentrations are still low and detection is most critical for patients.
A wide array of metagenomic study efforts are hampered by the same challenge: low concentrations of targets of interest combined with overwhelming amounts of background signal. Although PCR or naive DNA capture can be used when there are a small number of organisms of interest, design challenges become untenable for large numbers of targets.
A team of scientists at McMaster University (Hamilton, ON, Canada) and their colleagues have developed a sophisticated new tool that could help provide early warning of rare and unknown viruses in the environment and identify potentially deadly bacterial pathogens which cause sepsis. The new algorithm is an advanced tool that can help develop probes to capture trace quantities of pathogens, both known and unknown from a wide variety of situations, like the animal-to-human transmission of infections such as SARS-CoV-2 or monitor reservoirs in the environment for possible emerging pathogens.
The team successfully tested the probes on the entire family of coronaviruses, including SARS-CoV-2. The probes provide a shortcut by targeting, isolating and identifying the DNA sequences, specifically and simultaneously, that are shared among related organisms, most often due to evolutionary history or ancestry. To demonstrate the capabilities and effectiveness of the tool, The Hierarchical Unique Bait Design (HUBDesign), they designed and tested two probe sets: a coronavirus probe set capable of simultaneously detecting all sequenced coronaviruses, and a set of probes targeting bacterial pathogens associated with sepsis.
The majority (62.5%) of the probes have targets that are specific to one virus. Of the probes targeting multiple viruses, most (78.1%) target two or three. The remaining three sets of probes target loci specific to merbecoviruses and embecoviruses (both are Betacoronavirus subgenera) and loci common to the Deltacoronavirus genus. Both SARS-CoV-2 and HCoV-NL63 have probes at two levels in the hierarchy.
The HUBDesign probe set for sepsis pathogens contained 26,870 probes targeting bacterial pathogens, covering 2.09% of all nucleotides in the input dataset at an average depth of coverage of 3.64x. The investigators demonstrated the effectiveness of probes for capturing the incredibly wide array of pathogens associated with sepsis, a life-threatening and rapidly developing condition that occurs when the body overreacts to an infection which typically starts in the lungs, urinary tract, skin or gastrointestinal tract.
Hendrik Poinar, PhD, a Professor of Molecular Evolutionary Genetics and a lead author on the study, said, “We currently need faster, cheaper and more succinct ways to detect pathogens in human and environmental samples that democratize the hunt and this pipeline does exactly that.” The study was published on September 15, 2021 in the journal Cell Reports Methods.
Related Links:
McMaster University
A wide array of metagenomic study efforts are hampered by the same challenge: low concentrations of targets of interest combined with overwhelming amounts of background signal. Although PCR or naive DNA capture can be used when there are a small number of organisms of interest, design challenges become untenable for large numbers of targets.
A team of scientists at McMaster University (Hamilton, ON, Canada) and their colleagues have developed a sophisticated new tool that could help provide early warning of rare and unknown viruses in the environment and identify potentially deadly bacterial pathogens which cause sepsis. The new algorithm is an advanced tool that can help develop probes to capture trace quantities of pathogens, both known and unknown from a wide variety of situations, like the animal-to-human transmission of infections such as SARS-CoV-2 or monitor reservoirs in the environment for possible emerging pathogens.
The team successfully tested the probes on the entire family of coronaviruses, including SARS-CoV-2. The probes provide a shortcut by targeting, isolating and identifying the DNA sequences, specifically and simultaneously, that are shared among related organisms, most often due to evolutionary history or ancestry. To demonstrate the capabilities and effectiveness of the tool, The Hierarchical Unique Bait Design (HUBDesign), they designed and tested two probe sets: a coronavirus probe set capable of simultaneously detecting all sequenced coronaviruses, and a set of probes targeting bacterial pathogens associated with sepsis.
The majority (62.5%) of the probes have targets that are specific to one virus. Of the probes targeting multiple viruses, most (78.1%) target two or three. The remaining three sets of probes target loci specific to merbecoviruses and embecoviruses (both are Betacoronavirus subgenera) and loci common to the Deltacoronavirus genus. Both SARS-CoV-2 and HCoV-NL63 have probes at two levels in the hierarchy.
The HUBDesign probe set for sepsis pathogens contained 26,870 probes targeting bacterial pathogens, covering 2.09% of all nucleotides in the input dataset at an average depth of coverage of 3.64x. The investigators demonstrated the effectiveness of probes for capturing the incredibly wide array of pathogens associated with sepsis, a life-threatening and rapidly developing condition that occurs when the body overreacts to an infection which typically starts in the lungs, urinary tract, skin or gastrointestinal tract.
Hendrik Poinar, PhD, a Professor of Molecular Evolutionary Genetics and a lead author on the study, said, “We currently need faster, cheaper and more succinct ways to detect pathogens in human and environmental samples that democratize the hunt and this pipeline does exactly that.” The study was published on September 15, 2021 in the journal Cell Reports Methods.
Related Links:
McMaster University
Latest Molecular Diagnostics News
- Self-Collected HPV Testing Reaches Patients Missed by Routine Screening
- Genetic Risk Score Identifies Type 1 Diabetes in MODY Testing
- Comprehensive Genomic Testing Expands Treatment Options for Advanced Cancers
- Multi-Omics Analysis Identifies Additional Risk Genes in Hereditary Breast and Ovarian Cancer
- Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation
- Machine Learning Approach Expands Epigenetic Testing for Prenatal Genetic Disorders
- New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples
- Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth
- Liquid Biopsy Combines Multiple Signals for Cancer Detection in a Single Analysis
- Newborn Screening Program Adds Spinal Muscular Atrophy Testing Across England
- Blood Test Could Help Fast-Track Lymphoma Diagnosis in Resource-Limited Settings
- Liquid Biopsy Assay Enriches Tumor DNA for Early Detection and Monitoring
- Whole-Cell Genomic Analysis Expands the Potential of Liquid Biopsy
- Point-of-Care Multiplex PCR Test Submitted to FDA for Flu A/B and RSV Detection
- New PCR Assays Expand Cyclospora Testing for Outbreak Surveillance
- Single Liquid Biopsy Predicts Early Immunotherapy Benefit in Advanced Lung Cancer
Channels
Clinical Chemistry
view channel
Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40
C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more
Simple Whole-Blood Screen Identifies Elevated Bile Acids Linked to Liver Disease
Liver disease can progress silently until treatment options become more limited. Routine blood panels measure markers such as cholesterol, bilirubin, and triglycerides but typically do not include bile... Read more
Routine Urine Protein Testing Identifies Undiagnosed Chronic Kidney Disease
Chronic kidney disease (CKD) is a major cause of mortality worldwide and often progresses silently until advanced stages. Despite the availability of simple urine and blood tests, many cases remain undetected,... Read more
Longitudinal Heart Stress Assessment Improves Prediction of Cardiovascular Outcomes
Accurately predicting cardiovascular disease (CVD) risk in older adults is challenging when assessments rely on single, point-in-time biomarker measurements. Dynamic indicators that reflect evolving cardiac... Read moreHematology
view channel
New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
Inherited bone marrow failure syndromes (IBMFS) impair the bone marrow’s ability to produce sufficient healthy blood cells and are associated with an increased risk of early-onset myelodysplastic syndromes (MDS).... Read more
Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. In the UK, millions of tests are performed each year to diagnose disease, guide therapy,... Read moreImmunology
view channel
Immune Biomarkers May Predict Recurrent Checkpoint Inhibitor Arthritis
Inflammatory arthritis is a recognized immune-related adverse event in patients treated with immune checkpoint inhibitors (ICIs) for cancer. Between 20% and 50% of affected patients experience more than... Read more
Immune Cell Blood Test May Predict Melanoma Immunotherapy Response
Melanoma remains one of the deadliest skin cancers, although outcomes improve markedly when the disease is detected early. Immunotherapy has extended survival for many patients with advanced melanoma,... Read moreMicrobiology
view channel
Genetic Marker Identifies Emerging Resistance to Frontline Malaria Drugs
Artemisinin-based combination therapy remains central to controlling Plasmodium falciparum malaria, but emerging drug resistance is complicating treatment and surveillance. In Uganda and across sub-Saharan... Read more
Surveillance and Susceptibility Testing Track Rising Candida Auris in U.S.
Drug-resistant fungal infections are straining infection control and treatment in hospitals and long-term care facilities, where rapid transmission can lead to severe outcomes. Candida auris has expanded... Read morePathology
view channel
Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism
Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
30-Minute 3D Histology Tool Supports Intraoperative Glioma Margin Assessment
Glioma surgery depends on distinguishing infiltrative tumor from functional brain tissue, but microscopic spread beyond visible margins makes this difficult. Conventional frozen sections provide rapid... Read moreTechnology
view channel
Autonomous Robotic System Receives FDA Authorization for Blood Collection
Venipuncture is central to many diagnostic pathways, but routine blood collection can be affected by staffing constraints and procedural variability that influence consistency and patient experience.... Read more
Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read moreIndustry
view channel
AI-Powered Pathology Collaboration Supports Companion Diagnostic Development
Imagene AI has joined the Proscia Ready partner alliance to integrate its hematoxylin and eosin (H&E) screening tools and immunohistochemistry (IHC) image-analysis capabilities with Proscia’s Concentriq... Read more







